F-1: NewGenIvf Group Limited: Pre-Funded Warrant Filing

NewGenIvf Group Limited files a Form F-1 related to the offering of Class A Ordinary Shares and Pre-Funded Warrants, detailing its business operations, financial condition, and risk factors.

Summary

• NewGenIvf Group Limited has filed a Form F-1 registration statement concerning the offering of Class A Ordinary Shares and Pre-Funded Warrants.
• The filing details the company's business as an assisted reproductive services (ARS) provider in Asia-Pacific, with operations in Thailand, Cambodia, and Kyrgyzstan.
• The company has experienced significant revenue decreases in IVF treatment services in 2025 compared to 2024, alongside increased general and administrative expenses.
• NewGenIvf has been addressing Nasdaq's continued listing requirements through multiple reverse stock splits and has regained compliance with the minimum bid price rule.
• The company has also engaged in various debt financing activities, including issuing convertible notes, and has made strategic investments in digital assets and real estate.
• Significant risks are highlighted, including the potential for continued operating losses, competition, reliance on international clients, and the volatility of digital asset investments.
• The filing also details management changes, related party transactions, and the company's ongoing efforts to manage its financial and operational challenges.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as slightly negative due to the company's ongoing financial challenges, Nasdaq delisting concerns, and the dilutive nature of its financing activities, despite some operational progress.

Positives

• The company has regained compliance with Nasdaq's minimum bid price rule after implementing reverse stock splits.
• Strategic investments have been made in MicroSort technology and Nodexus Inc., potentially enhancing future service offerings.
• The company has a broad range of ARS services and a growing market presence in Asia-Pacific.
• Experienced management team with significant industry experience.
• The company has a strategy to expand service reach through acquisitions and partnerships.

Negatives

• Revenue from IVF treatment services decreased by approximately 28.11% in 2025 compared to 2024.
• Operating expenses increased significantly by approximately 291.05% in 2025 compared to 2024, primarily due to professional fees related to real estate development and increased staff costs.
• Gross profit decreased by approximately 47.68% in 2025 compared to 2024, with gross margins falling from 33.6% to 20.2%.
• The company has a limited operating history with its current platform of solutions, making future prospects difficult to predict.
• The company has experienced past deficiencies with Nasdaq listing requirements and faces ongoing risks related to maintaining compliance.
• The company has substantial outstanding convertible notes and payments related to equity investments.
• The company currently has no insurance coverage for its operations.

Risks

• The company may not be able to continue operating as a going concern, with cash and cash equivalents of approximately US$758,621 as of December 31, 2025, and outstanding convertible notes of $9,305,580.75.
• The fertility market is competitive, and failure to compete effectively could materially and adversely affect results of operations.
• NewGenIvf is undergoing a significant and rapid business transformation into a diversified conglomerate, which involves substantial risks and may not be successful.
• The company's new strategic initiatives may place significant strain on management and operational resources.
• The company's planned Solana digital assets purchase arrangement with White Lion is novel and subject to extreme volatility and regulatory scrutiny.
• Defects in certain leased property interests and failure to register certain lease agreements may materially and adversely affect the company's business, financial condition, results of operations, and prospects.
• If the company fails to meet the listing requirements of Nasdaq, its Class A Ordinary Shares could be delisted, which would reduce liquidity and market price.
• The company operates in a highly regulated industry and must comply with complex and evolving requirements; any lack of requisite approvals, licenses, or permits may have a material and adverse impact.

Future Outlook

The company plans to offer broad fertility services for fertility tourists across Asia Pacific, continue investing in laboratories and facilities, increase brand awareness and market share, and expand service reach through acquisitions and partnerships. The company expects its cost structure to evolve with business expansion, including increased headcount and higher staff costs.

Management Comments

• NewGenIvf believes that it can help address some of the key challenges of Asia-Pacific fertility industry.
• NewGenIvf believes that its current client base represents a small percentage of its total market opportunity.
• NewGenIvf believes that its expanding presence has resulted in a heightened awareness of the need to offer fertility services and the value it provides to its clients, which it believes will help facilitate its growth.
• NewGenIvf believes that there is potential in Asia in offering fertility treatments as a benefit for employees, particularly in companies with a large number of female employees of childbearing age.
• NewGenIvf believes that its business has benefited from, and will continue to benefit from, the convenience of its locations.

Industry Context

StockSavvy.ai notes that the assisted reproductive services (ARS) market in Asia-Pacific is substantial and growing, driven by societal shifts like later maternal age and increasing social acceptance of ARS. However, the market also faces challenges such as financial barriers, high treatment costs, and limited availability of services. The company's strategy to address these challenges through a broad range of services and geographic presence positions it to capitalize on market growth.

Comparison to Industry Standards

• The average cost per IVF cycle by NewGenIvf is around US$7,000 (excluding medication), which is positioned as relatively low cost compared to the US market.
• The company's Thailand clinic focuses on IVF and ancillary services, Cambodia clinic specializes in IVF and egg donation, and Kyrgyzstan clinic offers surrogacy services, providing a comprehensive offering that differentiates it from competitors.
• The company's acquisition of MicroSort technology provides exclusive rights to a pre-conception gender selection technology, potentially offering a competitive edge.
• The company's acquisition of Nodexus technology, related to cell sorting via the NX One platform, can facilitate gender selection and genetic disease detection in IVF processes.

Corporate Governance

Related Party Transactions

• Remuneration to directors Mr. Siu Wing Fung Alfred and Ms. Fong Hei Yue Tina totaled US$380,000 in 2024 and US$1.76 million in 2025 (including a one-time bonus of $750,000 for maintaining Nasdaq listing status and achieving targeted share capitalization level, and benefits paid).
• Service agreement with Harcourt Limited (controlled by Mr. Siu and Ms. Fong) resulted in payments of $230,772 in 2025 for administrative support fees, approved by the Board.
• Consulting services for fundraising and capital activities were provided by Mr. Daniel Siu and Mr. Jaspar Siu (sons of Mr. Siu) in 2025, receiving $219,045 and $65,000 respectively.
• Acquisition of a 2% minority equity interest and deposits for an additional 11% equity interest in PredicXion from Mr. Kong Yiu Cheung (a director and shareholder) in 2026, involving cash and share consideration totaling $2,287,500 and 3,722,223 Class A ordinary shares (adjusted for reverse stock splits).

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares as consideration for acquisitions and financing.
• Investors in the current offering may face limited liquidity for Pre-Funded Warrants as no market is expected to develop.
• The company's reliance on international clients could be impacted by global political and economic conditions, travel restrictions, or disease outbreaks.
• Fluctuations in exchange rates could materially and adversely affect the company's results of operations and the value of investments.
• Governmental control of currency conversion may limit the company's ability to utilize net revenue effectively.

Next Steps

• The company intends to use the net proceeds from the offering for investment in K25.ai, restructuring of debt securities, working capital (including manufacturing and deployment of Nodexus machines), and other general corporate purposes.
• The company plans to continue to scale up its existing laboratories and invest in upgrading its laboratories and facilities.
• NewGenIvf intends to increase brand awareness through social media promotions and marketing initiatives.
• NewGenIvf intends to expand its reach, services offering, and client base through strategic acquisitions and/or partnerships in Asia Pacific.
• The company plans to explore expanding its client base by offering its fertility services as part of corporate benefit programs in Asia.
• The company plans to establish its home country gynecologist partnership program.
• The company will continue to monitor market conditions and may suspend or terminate its share repurchase program at any time.
• The company will continue to monitor its compliance with Nasdaq listing requirements.

Key Dates

Recommendation

The company is in a transitional phase, with significant strategic shifts into new business areas like real estate and digital assets, alongside ongoing efforts to stabilize its core ARS business and address Nasdaq listing concerns. While there are positive developments in technology acquisition and market expansion, the financial performance shows a decline in core revenue and increased expenses, coupled with substantial debt and potential dilution from financing activities. The company's ability to execute its diversified strategy and manage its financial health remains a key concern. Therefore, a 'hold' recommendation is appropriate, pending clearer signs of sustained profitability and successful integration of new ventures.

Keywords

Assisted Reproductive Services, IVF Treatment, Fertility Referral, Pre-Funded Warrants, Class A Ordinary Shares, SEC Filing, Form F-1, Nasdaq Listing